Healthcare resource utilization and device-aided therapy discussions with eligible patients across the Parkinson's disease continuum: Revelations from the MANAGE-PD validation cohort

作者：Hubert H. Fernandez, Per Odin, David G. Standaert, Tove Henriksen, Joohi Jimenez‐Shahed, S. Metz, Ali Alobaidi, Connie H. Yan, Pavnit Kukreja, Juan Carlos Parra, Jorge Zamudio, Koray Onuk, Jack Wright, Angelo Antonini · 发表于：Parkinsonism & Related Disorders · 年份：2023 · DOI：10.1016/j.parkreldis.2023.105514 · 被引用次数：15 · 研究领域：Parkinson's Disease Mechanisms and Treatments、Assistive Technology in Communication and Mobility、Voice and Speech Disorders

INTRODUCTION: Device-aided therapy may improve the quality of life (QoL) for people with advanced Parkinson's disease (PD) and poorly controlled symptoms with oral therapy. MANAGE-PD is a validated tool classifying patients based on symptom control and advanced treatment eligibility. This study focused on patient/caregiver reported outcomes and healthcare resource utilization among patients grouped by MANAGE-PD categories. METHODS: Device-aided therapy-naïve patients receiving oral treatments were identified from the Adelphi Parkinson's Disease Programme. Patients were categorized (category 1 to 3) using MANAGE-PD. PD-specific QoL (PDQ-39), care partner burden (ZBI), satisfaction with current treatment, healthcare resource utilization, associated healthcare costs, and future treatment discussion with providers were measured. Categories were compared using ANOVA, t-test, chi square and adjusted regression analyses. RESULTS: Of the analytical sample (n = 2709), 18.9% were inadequately controlled on current therapy and potentially eligible for device-aided therapies (category 3). As expected, they had worse patient/caregiver reported outcomes versus patients in categories 1 or 2. However, the degree of difference in healthcare resource utilization, including: greater number of hospitalizations, emergency room (ER) visits and consultations, higher likelihood of being recipients of respite care, and greater PD treatment burden, was unexpected. Importantly, of patients in category ...